Monday, May 18, 2020

Halozyme Earns $15M Milestone Payment From Janssen

San Diego-based Halozyme TherapeuticsJanssen Biotech, as part of an existing liceknsing and collaboration agreement between the companies. According to the company, the payment comes as a result of the first commercial sale in the United States of Janssen's DARZALEX FASPROTM (daratumumab and hyaluronidase - fihj) utilizing ENHANZE.